|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Soulié P, Raymond E, Brienza S and
Cvitkovic E: Oxaliplatin: The first DACH platinum in clinical
practice. Bull Cancer. 84:665–673. 1997.(In French). PubMed/NCBI
|
|
3
|
Adam R, Wicherts DA, de Haas RJ, Ciacio O,
Lévi F, Paule B, Ducreux M, Azoulay D, Bismuth H and Castaing D:
Patients with initially unresectable colorectal liver metastases:
Is there a possibility of cure? J Clin Oncol. 27:1829–1835. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Duwe G, Knitter S, Pesthy S, Beierle AS,
Bahra M, Schmelzle M, Schmuck RB, Lohneis P, Raschzok N, Öllinger
R, et al: Hepatotoxicity following systemic therapy for colorectal
liver metastases and the impact of chemotherapy-associated liver
injury on outcomes after curative liver resection. Eur J Surg
Oncol. 43:1668–1681. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liang XB, Hou SH, Li YP, Wang LC, Zhang X
and Yang J: Irinotecan or oxaliplatin combined with 5-fluorouracil
and leucovorin as first-line therapy for advanced colorectal
cancer: A meta-analysis. Chin Med J (Engl). 123:3314–3318.
2010.PubMed/NCBI
|
|
6
|
Puente A, Fortea JI, Del Pozo C, Huelin P,
Cagigal ML, Serrano M, Cabezas J, Arias LM, Iruzubieta P, Cuadrado
A, et al: Porto-sinusoidal vascular disease associated to
oxaliplatin: An entity to think about it. Cells. 8:15062019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
André T, Boni C, Navarro M, Tabernero J,
Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F
and de Gramont A: Improved overall survival with oxaliplatin,
fluorouracil, and leucovorin as adjuvant treatment in stage II or
III colon cancer in the MOSAIC trial. J Clin Oncol. 27:3109–3116.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Erdem GU, Dogan M, Demirci NS and Zengin
N: Oxaliplatin-induced acute thrombocytopenia. J Cancer Res Ther.
12:509–514. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao J, van Mierlo K, Gomez-Ramirez J, Kim
H, Pilgrim CHC, Pessaux P, Rensen SS, van der Stok EP, Schaap FG,
Soubrane O, et al: Systematic review of the influence of
chemotherapy-associated liver injury on outcome after partial
hepatectomy for colorectal liver metastases. Br J Surg.
104:990–1002. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rubbia-Brandt L, Audard V, Sartoretti P,
Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane
O, Chaussade S, et al: Severe hepatic sinusoidal obstruction
associated with oxaliplatin-based chemotherapy in patients with
metastatic colorectal cancer. Ann Oncol. 15:460–466. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nassereddine S, Alsubait S and Tabbara I:
Sinusoidal obstruction syndrome (veno-occlusive disease) following
hematopoietic stem cell transplant: Insights and therapeutic
advances. Anticancer Res. 38:2597–2605. 2018.PubMed/NCBI
|
|
12
|
Nam SJ, Cho JY, Lee HS, Choe G, Jang JJ,
Yoon YS, Han HS and Kim H: Chemotherapy-associated hepatopathy in
korean colorectal cancer liver metastasis patients:
Oxaliplatin-based chemotherapy and sinusoidal injury. Korean J
Pathol. 46:22–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rubbia-Brandt L, Lauwers GY, Wang H, Majno
PE, Tanabe K, Zhu AX, Brezault C, Soubrane O, Abdalla EK, Vauthey
JN, et al: Sinusoidal obstruction syndrome and nodular regenerative
hyperplasia are frequent oxaliplatin-associated liver lesions and
partially prevented by bevacizumab in patients with hepatic
colorectal metastasis. Histopathology. 56:430–439. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fan CQ and Crawford JM: Sinusoidal
obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp
Hepatol. 4:332–346. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Russolillo N, Langella S, Perotti S, Lo
Tesoriere R, Forchino F and Ferrero A: Preoperative assessment of
chemotherapeutic associated liver injury based on indocyanine green
retention test. Int J Surg. 31:80–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu C, Ren X, Liu D and Zhang C:
Oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Toxicology. 460:1528822021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Overman MJ, Maru DM, Charnsangavej C,
Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA
and Kopetz S: Oxaliplatin-mediated increase in spleen size as a
biomarker for the development of hepatic sinusoidal injury. J Clin
Oncol. 28:2549–2555. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cayet S, Pasco J, Dujardin F, Besson M,
Orain I, De Muret A, Miquelestorena-Standley E, Thiery J, Genet T
and Le Bayon AG: Diagnostic performance of contrast-enhanced
CT-scan in sinusoidal obstruction syndrome induced by chemotherapy
of colorectal liver metastases: Radio-pathological correlation. Eur
J Radiol. 94:180–190. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han NY, Park BJ, Kim MJ, Sung DJ and Cho
SB: Hepatic parenchymal heterogeneity on contrast-enhanced CT scans
following oxaliplatin-based chemotherapy: Natural history and
association with clinical evidence of sinusoidal obstruction
syndrome. Radiology. 276:766–774. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Couto M and Cates C: Laboratory guidelines
for animal care. Methods Mol Biol. 1920:407–430. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu Y, Wu S, Xiang B, Li L and Lin Y:
Curcumin attenuates oxaliplatin-induced liver injury and oxidative
stress by activating the Nrf2 pathway. Drug Des Devel Ther.
14:73–85. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li X, Zhang ZS, Zhang XH, Yang SN, Liu D,
Diao CR, Wang H and Zheng FP: Cyanidin inhibits EMT induced by
oxaliplatin via targeting the PDK1-PI3K/Akt signaling pathway. Food
Funct. 10:592–601. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miyagi A, Kawashiri T, Shimizu S,
Shigematsu N, Kobayashi D and Shimazoe T: Dimethyl fumarate
attenuates oxaliplatin-induced peripheral neuropathy without
affecting the anti-tumor activity of oxaliplatin in rodents. Biol
Pharm Bull. 42:638–644. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rubbia-Brandt L, Tauzin S, Brezault C,
Delucinge-Vivier C, Descombes P, Dousset B, Majno PE, Mentha G and
Terris B: Gene expression profiling provides insights into pathways
of oxaliplatin-related sinusoidal obstruction syndrome in humans.
Mol Cancer Ther. 10:687–696. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zou X, Wang Y, Peng C, Wang B, Niu Z, Li Z
and Niu J: Magnesium isoglycyrrhizinate has hepatoprotective
effects in an oxaliplatin-induced model of liver injury. Int J Mol
Med. 42:2020–2030. 2018.PubMed/NCBI
|
|
27
|
Kim MJ, Han SW, Lee DW, Cha Y, Lee KH and
Kim TY, Oh DY, Kim SH, Im SA, Bang YJ and Kim TY: Splenomegaly and
its associations with genetic polymorphisms and treatment outcome
in colorectal cancer patients treated with adjuvant FOLFOX. Cancer
Res Treat. 48:990–997. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
El Chediak A, Haydar AA, Hakim A, Massih
SA, Hilal L, Mukherji D, Temraz S and Shamseddine A: Increase in
spleen volume as a predictor of oxaliplatin toxicity. Ther Clin
Risk Manag. 14:653–657. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang YF, Huang Y, Ni YH and Xu ZM:
Systematic elucidation of the mechanism of geraniol via network
pharmacology. Drug Des Devel Ther. 13:1069–1075. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsikas D: Assessment of lipid peroxidation
by measuring malondialdehyde (MDA) and relatives in biological
samples: Analytical and biological challenges. Anal Biochem.
524:13–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nordlinger B, Sorbye H, Glimelius B,
Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole
ET, Finch-Jones M, et al: Perioperative FOLFOX4 chemotherapy and
surgery versus surgery alone for resectable liver metastases from
colorectal cancer (EORTC 40983): Long-term results of a randomised,
controlled, phase 3 trial. Lancet Oncol. 14:1208–1215. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vreuls CP, Van Den Broek MA, Winstanley A,
Koek GH, Wisse E, Dejong CH, Olde Damink SW, Bosman FT and Driessen
A: Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect
of oxaliplatin in colorectal liver metastases. Histopathology.
61:314–318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tajima H, Ohta T, Miyashita T, Nakanuma S,
Matoba M, Miyata T, Sakai S, Okamoto K, Makino I, Kinoshita J, et
al: Oxaliplatin-based chemotherapy induces extravasated platelet
aggregation in the liver. Mol Clin Oncol. 3:555–558. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Robinson SM, Mann J, Vasilaki A, Mathers
J, Burt AD, Oakley F, White SA and Mann DA: Pathogenesis of FOLFOX
induced sinusoidal obstruction syndrome in a murine chemotherapy
model. J Hepatol. 59:318–326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lu Y, Lin Y, Huang X, Wu S, Wei J and Yang
C: Oxaliplatin aggravates hepatic oxidative stress, inflammation
and fibrosis in a non-alcoholic fatty liver disease mouse model.
Int J Mol Med. 43:2398–2408. 2019.PubMed/NCBI
|
|
36
|
Yang L, Ding Y, Rao S, Chen C and Zeng M:
T1 mapping on Gd-EOB-DTPA-enhanced MRI for the
prediction of oxaliplatin-induced liver injury in a mouse model. J
Magn Reson Imaging. 53:896–902. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Oneda E and Zaniboni A: Adjuvant treatment
of colon cancer with microsatellite instability-the state of the
art. Crit Rev Oncol Hematol. 169:1035372022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xia T, Zhang J, Han L, Jin Z, Wang J, Li
X, Man S, Liu C and Gao W: Protective effect of magnolol on
oxaliplatin-induced intestinal injury in mice. Phytother Res.
33:1161–1172. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Valla DC and Cazals-Hatem D: Sinusoidal
obstruction syndrome. Clin Res Hepatol Gastroenterol. 40:378–385.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McCarty JH: αvβ8 integrin adhesion and
signaling pathways in development, physiology and disease. J Cell
Sci. 133:jcs2394342020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Munger JS, Huang X, Kawakatsu H, Griffiths
MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, et
al: The integrin alpha v beta 6 binds and activates latent TGF beta
1: A mechanism for regulating pulmonary inflammation and fibrosis.
Cell. 96:319–328. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Trostchansky A, Moore-Carrasco R and
Fuentes E: Oxidative pathways of arachidonic acid as targets for
regulation of platelet activation. Prostaglandins Other Lipid
Mediat. 145:1063822019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Capdevila JH, Falck JR and Harris RC:
Cytochrome P450 and arachidonic acid bioactivation. Molecular and
functional properties of the arachidonate monooxygenase. J Lipid
Res. 41:163–181. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sheets JJ, Mason JI, Wise CA and Estabrook
RW: Inhibition of rat liver microsomal cytochrome P-450 steroid
hydroxylase reactions by imidazole antimycotic agents. Biochem
Pharmacol. 35:487–491. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pikuleva IA: Cholesterol-metabolizing
cytochromes P450. Drug Metab Dispos. 34:513–520. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jarzabek MA, Proctor WR, Vogt J, Desai R,
Dicker P, Cain G, Raja R, Brodbeck J, Stevens D, van der Stok EP,
et al: Interrogation of transcriptomic changes associated with
drug-induced hepatic sinusoidal dilatation in colorectal cancer.
PLoS One. 13:e1980992018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lu SC, Mato JM, Espinosa-Diez C and Lamas
S: MicroRNA-mediated regulation of glutathione and methionine
metabolism and its relevance for liver disease. Free Radic Biol
Med. 100:66–72. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tabassum H, Waseem M, Parvez S and Qureshi
MI: Oxaliplatin-induced oxidative stress provokes toxicity in
isolated rat liver mitochondria. Arch Med Res. 46:597–603. 2015.
View Article : Google Scholar : PubMed/NCBI
|
